Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer

A. Y.C. Chang; A. Solan; B. H. Kaplan; S. E. Vogl; F. J. Camacho; S. G. Taylor IV

doi:10.1097/00000421-198810000-00005

Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer

A. Y.C. Chang, A. Solan, B. H. Kaplan, S. E. Vogl, F. J. Camacho, S. G. Taylor IV

Research output: Contribution to journal › Article › peer-review

Abstract

Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m² i.v. and m-AMSA at 50 mg/m² i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m² and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.

Original language	English (US)
Pages (from-to)	535-537
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	11
Issue number	5
DOIs	https://doi.org/10.1097/00000421-198810000-00005
State	Published - 1988
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-198810000-00005

Cite this

@article{3ff0575985e6488d84199ce0ecdfb530,

title = "Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer",

abstract = "Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.",

author = "Chang, {A. Y.C.} and A. Solan and Kaplan, {B. H.} and Vogl, {S. E.} and Camacho, {F. J.} and {Taylor IV}, {S. G.}",

year = "1988",

doi = "10.1097/00000421-198810000-00005",

language = "English (US)",

volume = "11",

pages = "535--537",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer

AU - Chang, A. Y.C.

AU - Solan, A.

AU - Kaplan, B. H.

AU - Vogl, S. E.

AU - Camacho, F. J.

AU - Taylor IV, S. G.

PY - 1988

Y1 - 1988

N2 - Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.

AB - Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023706675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023706675&partnerID=8YFLogxK

U2 - 10.1097/00000421-198810000-00005

DO - 10.1097/00000421-198810000-00005

M3 - Article

C2 - 3177254

AN - SCOPUS:0023706675

SN - 0277-3732

VL - 11

SP - 535

EP - 537

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 5

ER -

Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this